^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

Published date:
09/12/2022
Excerpt:
Mersana Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).